{
    "title": "FDA seeks more data on Sarepta muscle disorder drug, shares slump",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-2809498/FDA-seeks-data-Sarepta-muscle-disorder-drug-shares-slump.html",
    "date": "2014-10-27",
    "keywords": [
        "drug",
        "approval",
        "application",
        "monday",
        "disorder",
        "fda",
        "biomarker",
        "percent",
        "muscle",
        "october",
        "marketing",
        "company",
        "decision",
        "year",
        "midstage",
        "dystrophin",
        "reliability",
        "ability",
        "gmt",
        "email",
        "groveroct",
        "setback",
        "move",
        "market",
        "value",
        "food",
        "lead",
        "drugthe",
        "timeline",
        "study",
        "latestage",
        "sarepta",
        "applicationeteplirsen",
        "dystrophy",
        "movement",
        "die",
        "age",
        "submission",
        "middle",
        "competitor",
        "prosensa",
        "nv",
        "drugat",
        "heart",
        "protein",
        "indicator",
        "state",
        "conditioneteplirsen",
        "prosensas",
        "section",
        "gene",
        "lack",
        "strategy",
        "viability",
        "benefit",
        "capital",
        "analyst",
        "debjit",
        "chattopadhyay",
        "assessment",
        "drystrophin",
        "statementthe",
        "regulator",
        "reluctance",
        "premature",
        "trial",
        "drisapersen",
        "dystrophinhowever",
        "agency",
        "april",
        "path",
        "goal",
        "surrogate",
        "pit",
        "saidif",
        "possibility",
        "high",
        "nasdaq",
        "stock",
        "kalluvila",
        "saumyadeb",
        "chakrabarty"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}